Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non-Current Deffered Revenue (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $4.0 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Non-Current Deffered Revenue changed 0.0% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Sep 2024, changed 0.0%, and an annual FY2023 reading of $4.0 million, changed 0.0% over the prior year.
  • Non-Current Deffered Revenue was $4.0 million for Q3 2024 at Oramed Pharmaceuticals, roughly flat from $4.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $4.0 million in Q3 2022 and bottomed at $2.0 million in Q2 2022.
  • Average Non-Current Deffered Revenue over 3 years is $3.7 million, with a median of $4.0 million recorded in 2022.
  • Peak annual rise in Non-Current Deffered Revenue hit 100.0% in 2023, while the deepest fall reached 0.0% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then changed by 0.0% to $4.0 million in 2024.
  • Business Quant data shows Non-Current Deffered Revenue for ORMP at $4.0 million in Q3 2024, $4.0 million in Q2 2024, and $4.0 million in Q1 2024.